Metsera

Market position

Metsera competed in the obesity and cardiometabolic market dominated by Novo Nordisk (semaglutide/Wegovy) and Eli Lilly (tirzepatide/Zepbound); one cited analysis projected the GLP-1 receptor agonist market at $168 billion across 68 pharmaceutical markets by 2033. Its perceived strategic value was reflected in a contested sale process in which Pfizer and Novo Nordisk both bid, with Pfizer prevailing on the basis of greater regulatory certainty.

Metsera sought to differentiate through its HALO peptide stabilization and lipidation platform, which enables peptides to bind simultaneously to albumin and a drug target for a half-life approaching that of albumin and exceeding other NuSH peptides, supporting monthly and potentially quarterly dosing. It also emphasized a modular library of gut hormone peptides that could be combined across mechanisms (GLP-1, amylin/calcitonin, GIP, glucagon), both injectable and oral formulations, and reported tolerability advantages including a placebo-like diarrhea profile for MET-097i.

Technology

The company's approach centered on peptides and peptide-antibody conjugates rather than small molecules, citing greater specificity, lower off-target risk and in-house experience with peptide manufacturing at scale. Core assets included the Zihipp-derived library of over 20,000 gut hormone peptides, the HALO stabilization and lipidation platform for ultra-long half-life, and oral absorption technology acquired from an undisclosed company to enable oral administration of injectable peptides.

Go-to-market

Prior to acquisition Metsera had no commercialized products and said it had not pursued big-pharma partnerships for its programs, planning instead to advance candidates through Phase 3 itself, with cardiovascular and other outcomes potentially as primary endpoints and weight loss as a secondary endpoint. Following the Pfizer acquisition, its candidates are to be advanced using Pfizer's global development, manufacturing and commercial infrastructure, with Pfizer's CEO suggesting therapies could reach the market as soon as 2028.

People with overweight or obesity and related cardiometabolic conditions, including trial populations of non-diabetic participants with overweight or obesity.

Geography

Headquartered in New York City, with technology originating from London-based Zihipp and an R&D leader affiliated with Imperial College London; contract manufacturing capacity was to be built by Amneal in India. Clinical trials included U.S. enrollment, and Pfizer noted risks associated with Metsera conducting clinical trials and preclinical studies outside the United States.

History

Founded in 2022 and headquartered in New York, Metsera acquired London-based Zihipp Limited while in stealth, obtaining a library of more than 20,000 gut hormone peptides; Zihipp chair Stephen R. Bloom, an early GLP-1 appetite researcher and head of drug development, metabolism, digestion and reproduction at Imperial College London, became Metsera's R&D leader. Metsera emerged from stealth in April 2024 with $290 million, raised a $215 million Series B in November 2024 taking total capital to over $500 million, and filed for an IPO reported in mid-2025, subsequently trading on Nasdaq as MTSR. It signed a merger agreement with Pfizer on September 21, 2025, received unsolicited proposals from Novo Nordisk that its board deemed a Superior Company Proposal, agreed an amended Pfizer merger agreement on November 7, 2025 with increased upfront cash and revised CVR terms, and the Pfizer acquisition closed on November 13, 2025.

Risks & controversies

Pfizer's disclosure notice cited risks including integration failure, unknown liabilities, uncertainty over commercial success of Metsera's pipeline, reliance on third parties for trials and manufacturing, potential side effects or safety risks of candidates, risks tied to Metsera's license and collaboration agreements, and intellectual property protection; the acquisition was described as dilutive to Pfizer through 2030. The sale process itself was contested, with Novo Nordisk's competing proposals raising regulatory-review timing concerns, and analysts publicly questioning whether Metsera was worth the contested price.